Avenue Therapeutics (ATXI) Competitors

→ “Forget Tesla, this is Elon’s Next Big Thing” (From InvestorPlace) (Ad)

$0.12

-0.01 (-7.41%)

(As of 04/15/2024 ET)

ATXI vs. UPC, CVKD, ALZN, SEEL, GRAY, ENVB, PTIX, SONN, PULM, and MBIO

Should you be buying Avenue Therapeutics stock or one of its competitors? The main competitors of Avenue Therapeutics include Universe Pharmaceuticals (UPC), Cadrenal Therapeutics (CVKD), Alzamend Neuro (ALZN), Seelos Therapeutics (SEEL), Graybug Vision (GRAY), Enveric Biosciences (ENVB), Protagenic Therapeutics (PTIX), Sonnet BioTherapeutics (SONN), Pulmatrix (PULM), and Mustang Bio (MBIO). These companies are all part of the "pharmaceutical preparations" industry.

Avenue Therapeutics vs.

Avenue Therapeutics (NASDAQ:ATXI) and Universe Pharmaceuticals (NYSE:UPC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

: In the previous week, Avenue Therapeutics had 2 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 2 mentions for Avenue Therapeutics and 0 mentions for Universe Pharmaceuticals. Avenue Therapeutics' average media sentiment score of 1.43 beat Universe Pharmaceuticals' score of 0.00 indicating that Avenue Therapeutics is being referred to more favorably in the media.
Company Overall Sentiment
Avenue Therapeutics Positive
Universe Pharmaceuticals Neutral
: 17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 1.8% of Avenue Therapeutics shares are held by company insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: Avenue Therapeutics has a beta of -0.24, indicating that its share price is 124% less volatile than the S&P 500. Comparatively, Universe Pharmaceuticals has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500.
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
3.00
Universe Pharmaceuticals
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
: Avenue Therapeutics received 147 more outperform votes than Universe Pharmaceuticals when rated by MarketBeat users.
Company Underperform Outperform
Avenue Therapeutics Outperform Votes
147
60.25%
Underperform Votes
97
39.75%
Universe Pharmaceuticals N/A N/A
: Company Net Margins Return on Equity Return on Assets
Avenue Therapeutics N/A N/A -335.11%
Universe Pharmaceuticals N/A N/A N/A
: Universe Pharmaceuticals has higher revenue and earnings than Avenue Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Avenue Therapeutics N/A N/A -$10.38M -$1.27 -0.10
Universe Pharmaceuticals $32.31M 0.24 -$6.16M N/A N/A

Company	Overall Sentiment
Avenue Therapeutics	Positive
Universe Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Universe Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Company	Underperform	Outperform
Avenue Therapeutics	Outperform Votes 147 60.25%	Underperform Votes 97 39.75%
Universe Pharmaceuticals	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Avenue Therapeutics	N/A	N/A	-335.11%
Universe Pharmaceuticals	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avenue Therapeutics	N/A	N/A	-$10.38M	-$1.27	-0.10
Universe Pharmaceuticals	$32.31M	0.24	-$6.16M	N/A	N/A

Summary

Avenue Therapeutics and Universe Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.

Ad InvestorPlace

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

>>Check out what this A.I. Perfect Storm is<<

Get Avenue Therapeutics News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATXI vs. The Competition

Export to Excel

Metric	Avenue Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6M	$6.40B	$4.74B	$7.61B
Dividend Yield	N/A	3.10%	5.45%	3.96%
P/E Ratio	-0.10	6.34	166.93	13.45
Price / Sales	N/A	314.92	2,458.17	89.07
Price / Cash	N/A	20.25	33.16	28.20
Price / Book	4.17	5.52	4.67	4.26
Net Income	-$10.38M	$137.51M	$99.83M	$211.03M
7 Day Performance	-14.91%	-5.20%	-4.39%	-4.55%
1 Month Performance	-20.63%	-4.49%	-3.20%	-2.06%
1 Year Performance	-88.53%	2.63%	12.54%	6.74%

Avenue Therapeutics Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UPC Universe Pharmaceuticals	0 of 5 stars	$1.80 flat	N/A	-31.1%	$6.52M	$32.31M	0.00	225
CVKD Cadrenal Therapeutics	2.8762 of 5 stars	$0.41 -19.7%	$3.50 +756.4%	-70.2%	$6.54M	N/A	-0.59	4	Gap Up High Trading Volume
ALZN Alzamend Neuro	1.7678 of 5 stars	$0.91 +3.4%	$22.50 +2,363.5%	-91.6%	$6.28M	N/A	-0.92	4	Short Interest ↓ Positive News Gap Up
SEEL Seelos Therapeutics	2.7544 of 5 stars	$0.49 -3.9%	$70.00 +14,070.0%	-98.1%	$6.76M	$2.20M	0.00	15	Positive News
GRAY Graybug Vision	0 of 5 stars	$4.33 +0.2%	N/A	+28.7%	$6.80M	N/A	-2.50	27	Gap Up High Trading Volume
ENVB Enveric Biosciences	1.555 of 5 stars	$0.94 +2.2%	$10.00 +962.5%	-39.4%	$6.86M	N/A	-0.12	7	Positive News
PTIX Protagenic Therapeutics	0 of 5 stars	$1.57 +2.0%	N/A	-18.8%	$6.95M	N/A	-1.36	N/A	Gap Down
SONN Sonnet BioTherapeutics	1.3796 of 5 stars	$1.96 -3.4%	$88.70 +4,425.5%	-77.5%	$6.02M	$150,000.00	0.00	12	Short Interest ↓ News Coverage Positive News Gap Up
PULM Pulmatrix	1.4867 of 5 stars	$1.92 +1.6%	$10.00 +420.8%	-29.6%	$7.01M	$7.30M	-0.50	28	Analyst Report News Coverage Gap Up
MBIO Mustang Bio	1.9708 of 5 stars	$0.68 -1.4%	$17.25 +2,421.9%	-88.9%	$7.11M	N/A	-0.11	80	News Coverage Gap Up

Related Companies and Tools

Related Companies:

Top 10 Stock Comparisons

This page (NASDAQ:ATXI) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Avenue Therapeutics (ATXI) Competitors

ATXI vs. UPC, CVKD, ALZN, SEEL, GRAY, ENVB, PTIX, SONN, PULM, and MBIO

Avenue Therapeutics vs.

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATXI vs. The Competition

Avenue Therapeutics Competitors List

Related Companies and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info